Alimera banks $40M; Epizyme snags $4M GSK milestone; Noven claims PhIII success for menopause therapy;

Conversation on Twitter :

 @FierceBiotech: Special report: The Top Phase III Disasters of 2012. Report | Follow @FierceBiotech

 @JohnCFierce: First "complete virtuous circle" for crowdfunding biotech model in France. Interesting idea. Hard to pull off. Release | Follow @JohnCFierce

 @RyanMFierce: Nice to see VentiRx deal with Celgene, and a win for a biotech with small virtual staff and big potential. More | Follow @RyanMFierce

> Alimera Sciences has raised $40 million from the sale of its shares to institutional investors. Report

> Epizyme has earned a $4 million milestone from its partnership with GlaxoSmithKline ($GSK). Release

> The Leukemia and Lymphoma Society and Celgene have agreed to partner on research into new blood cancer treatments. Release

> Noven Pharmaceuticals says it has gathered positive data from its Phase III studies "evaluating low-dose mesylate salt of paroxetine (LDMP; 7.5 mg/day) for the treatment of moderate to severe vasomotor symptoms associated with menopause." Release

Pharma News

@FiercePharma: Novartis drops its legal case against U.K. doc group that nixed Lucentis. The group changed policy after Novartis cut price. More | Follow @FiercePharma

> Private equity's pharma hopes exemplified by Nycomed. More

> Celgene's Abraxane delivers in melanoma study. Article

> Sanofi, Bristol revamp Plavix partnership for post-patent world. Story

> Sanofi buying Genfar as it rolls across Latin America. News

Medical Device News

 @FierceMedDev: Paper Dx could become even cheaper if this new research finding catches on. More | Follow @FierceMedDev

 @MarkHFierce: The U.S. breast implant market will grow modestly in the coming years, Millennium estimates, but Europe's won't. More | Follow @MarkHFierce

 @DamianFierce: Fresh off its $100M IPO, Globus Medical got FDA approval for its spinal disc implant. More | Follow @DamianFierce

> Analysts: Device market growth will outpace pharma by 2018. News

> Allergan abandons pursuit of FDA clearance for teen use of Lap-Band obesity device. Article

Biomarkers News

> Singulex heads for $86.25M flotation. Item

> RNA profiles pinpoint the course of MS. Story

> Biomarkers boost success, cut costs in breast cancer clinical trials. Article

> Singulex heads for $86.25M flotation. More

Drug Delivery News

> Pfizer pays out on Antares drug delivery tech agreement. News

> Nanoparticles getting under your skin? Maybe not, actually. Story

> Noven ADHD patch heads into Phase II. Article

And Finally… Investigators at Texas A&M have been probing into the reason why phobias are so difficult to treat. Story